PolarityTE to Present at the Jefferies 2018 Global Healthcare Conference
May 30 2018 - 08:00AM
PolarityTE™, Inc. (Nasdaq:COOL) today announced it will present at
the Jefferies 2018 Global Healthcare Conference on Thursday, June
7, 2018 at 2:30pm ET. Denver M. Lough, MD, PhD, Chairman and
CEO and Edward Swanson, MD, Executive VP and COO will provide an
overview of PolarityTE’s science and platform technology, including
SkinTE, a human cellular and tissue-based product derived from a
patient’s own skin.
The presentation will be webcast live and can be accessed by
visiting the IR Calendar in the Investor Relations tab at
www.polarityTE.com, or by clicking here.
About PolarityTE™PolarityTE is
a commercial-stage biotechnology and regenerative biomaterials
company focused on transforming the lives of patients by
discovering, designing and developing a range of regenerative
tissue products and biomaterials for the fields of medicine,
biomedical engineering and material sciences. The PolarityTE
platform technology begins with a small piece of the patient’s own,
or autologous, healthy tissue, rather than artificially manipulated
individual cells. From this small piece of healthy autologous
tissue, the company creates an easily deployable, dynamic and
self-propagating product designed to enhance and stimulate the
patient’s own cells to regenerate the target tissues. Rather than
manufacturing with synthetic and foreign materials within
artificially engineered environments, PolarityTE manufactures with
the patient’s own tissue and uses the patient’s own body to support
the regenerative process to create the same tissue from which it
was derived. PolarityTE’s innovative method is intended to promote
and accelerate growth of the patient’s tissues to undergo a form of
effective regenerative healing.
About SkinTE™SkinTE is intended
to be used by physicians or other appropriate healthcare providers
for homologous uses of skin tissues/integument. Patients who have
suffered from an event, disease, process or acquired deficit that
results in the functional loss or void of skin/integument systems
can receive SkinTE as an adjunct and/or in place of split-thickness
skin grafting, full-thickness grafting, temporizing skin coverage
and/or skin substitute products.
SkinTE is for autologous use only. Aseptic
technique during harvest and deployment of SkinTE is mandatory.
SkinTE use is contraindicated in patients who have suffered
autoimmune responses to the auto-transplantation of their own
tissues.
SkinTE is regulated by the FDA as an HCT/P
solely under Section 361 of the Public Health Service Act and 21
CFR 1271. The FDA has specific regulations governing HCT/Ps. HCT/Ps
that meet the criteria for regulation solely under Section 361 of
the Public Health Service Act and 21 CFR 1271 (361 HCT/Ps) are not
subject to pre-market clearance or approval requirements, but are
subject to post-market regulatory requirements.
Forward Looking
StatementsCertain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward looking
statements contained in this release relate to, among other things,
the Company’s ongoing compliance with the requirements of The
NASDAQ Stock Market and the Company’s ability to maintain the
closing bid price requirements of The NASDAQ Stock Market on a post
reverse split basis. They are generally identified by words such as
“believes,” “may,” “expects,” “anticipates,” “intend,” “plan,”
“will,” “would,” “should” and similar expressions. Readers should
not place undue reliance on such forward-looking statements, which
are based upon the Company’s beliefs and assumptions as of the date
of this release. The Company’s actual results could differ
materially due to risk factors and other items described in more
detail in the “Risk Factors” section of the Company’s Annual
Reports and other filings with the SEC (copies of which may be
obtained at www.sec.gov). Subsequent events and developments may
cause these forward-looking statements to change. The Company
specifically disclaims any obligation or intention to update or
revise these forward-looking statements as a result of changed
events or circumstances that occur after the date of this release,
except as required by applicable law. Our actual results could
differ materially due to risk factors and other items described in
more detail in the “Risk Factors” section of the Company’s Annual
Reports and other filings with the SEC (copies of which may be
obtained at www.sec.gov).
CONTACT
Investors:Rich
Haerleir@PolarityTE.com(385) 237-2365
Media:David SchullRusso
Partners LLCDavid.Schull@RussoPartnersLLC.com(858)
717-2310
Corner Growth Acquisition (NASDAQ:COOL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Corner Growth Acquisition (NASDAQ:COOL)
Historical Stock Chart
From Mar 2023 to Mar 2024